Luca Bertolaccini, Thoracic Surgeon at IEO – European Institute of Oncology and Associate Editor of the European Journal of Cardio-Thoracic Surgery at Oxford University Press, shared a post on LinkedIn about a paper he co-authored with colleagues published in The Lancet Respiratory Medicine:
“Published in The Lancet Respiratory Medicine!
Our Invited Commentary – ‘Biological Staging in Early-Stage Non-Small-Cell Lung Cancer: Molecular Risk-Guided Adjuvant Therapy’ – reflects on how tumor biology is transforming clinical decision-making in early-stage NSCLC.
Moving beyond tumor size and anatomic stage, molecular profiling and genomic assays are offering new ways to identify patients at higher risk of relapse, ensuring that adjuvant therapies are given to those most likely to benefit.
The AIM-HIGH trial marks an important step, showing that risk-based stratification can significantly reduce recurrence, opening the door to a future where chemotherapy, immunotherapy, and targeted agents are guided by biology rather than anatomy alone.
A shift toward personalized medicine in thoracic oncology.”
Title: Biological staging in early-stage non-small-cell lung cancer: molecular risk-guided adjuvant therapy
Authors: Luca Bertolaccini, Lorenzo Spaggiari
You can read the Full Article in The Lancet Respiratory Medicine.
More posts featuring Luca Bertolaccini.